JPS6344521A - Method for preventing adsorption of bromhexine hydrochloride - Google Patents

Method for preventing adsorption of bromhexine hydrochloride

Info

Publication number
JPS6344521A
JPS6344521A JP61187395A JP18739586A JPS6344521A JP S6344521 A JPS6344521 A JP S6344521A JP 61187395 A JP61187395 A JP 61187395A JP 18739586 A JP18739586 A JP 18739586A JP S6344521 A JPS6344521 A JP S6344521A
Authority
JP
Japan
Prior art keywords
bromhexine hydrochloride
packaging material
granules
adsorption
polymer packaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP61187395A
Other languages
Japanese (ja)
Other versions
JPH0739341B2 (en
Inventor
Takuya Kukita
茎田 卓也
Akihiko Okamoto
昭彦 岡本
Yoshie Yamaguchi
山口 美江
Shozo Kochiwa
小団扇 省三
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP61187395A priority Critical patent/JPH0739341B2/en
Publication of JPS6344521A publication Critical patent/JPS6344521A/en
Publication of JPH0739341B2 publication Critical patent/JPH0739341B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

PURPOSE:To prevent the adsorption of bromhexine hydrochloride to a polymer packaging material during packaging and storing in the polymer packaging material, by adding a sugar to bromhexine hydrochloride and granulating the mixture. CONSTITUTION:Bromhexine hydrochloride used widely as an expectorant is compounded with a sugar selected from monosaccharide and disaccharide (e.g. mannitol, sorbitol, glucose, etc.) and granulated by conventional method using conventional binder such as hydroxypropyl cellulose. The granular agent can be packaged with a polymer packaging material without causing the adsorption of bromhexine hydrochloride to said material and, accordingly, the content of the active component in the granule can be maintained over a long period.

Description

【発明の詳細な説明】 [産業上の利用分野] 本発明は、粒剤中の塩酸ブロムヘキシンの高分子包材へ
の吸着防止方法に関する。
DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a method for preventing adsorption of bromhexine hydrochloride in granules to a polymer packaging material.

[従来の技術] 従来、塩酸ブロムヘキシンにデンプン、結晶セルロース
等を配合し、常法により粒剤とし、これをガラスピンま
たはステンレス製容器で包装し、用時秤量し小1分けし
ていた。
[Prior Art] In the past, starch, crystalline cellulose, etc. were blended with bromhexine hydrochloride, granules were made by a conventional method, the granules were packaged with glass pins or stainless steel containers, and the granules were weighed and divided into small portions at the time of use.

[発明が解決しようとする問題点コ しかしながら、使用の都度これを秤量し小分けするのは
多忙時には煩瑣であるので、予め高分子包材に分包して
保存しておくのが実務上便利である。
[Problems to be Solved by the Invention]However, weighing and dividing the product each time it is used is a hassle when you are busy, so it is practical to store it in advance by packaging it in polymeric packaging material. be.

ところが、本発明者らの研究の結果、塩酸ブロムヘキシ
ンは、配合する物質の種類(例えばデンプン、結晶セル
ロース等)により高分子包材に吸着し分包剤中の含量が
減少するという問題が生じることが明らかとなった。
However, as a result of research conducted by the present inventors, it has been found that bromhexine hydrochloride may be adsorbed to polymer packaging materials depending on the type of substance to be blended (e.g., starch, crystalline cellulose, etc.), resulting in a problem in which the content in the packaging agent decreases. became clear.

塩酸ブロムヘキシンは優れた去挟薬として広く利用きれ
ている薬物であるが、その投与量は1回に4mg程度の
少量にすぎない。
Bromhexine hydrochloride is a drug that is widely used as an excellent expectorant, but its dosage is only a small amount of about 4 mg at a time.

従って、保存の間に粒剤中の塩酸ブロムヘキシンが高分
子包材に吸着して微量といえどもその含量を減すること
はその薬効に重大な影響を与える。
Therefore, if the bromhexine hydrochloride in the granules is adsorbed to the polymeric packaging material during storage and its content is reduced, even if only by a small amount, this has a significant effect on its medicinal efficacy.

本発明の目的は、高分子包材により分包した粒剤中の塩
酸ブロムヘキシンが高分子包材に吸着するのを防止する
方法を提供することにある。
An object of the present invention is to provide a method for preventing bromhexine hydrochloride contained in granules packaged with a polymeric packaging material from adsorbing to the polymeric packaging material.

[問題点を解決するための手段] 本発明の方法は、塩酸ブロムヘキシンを含有する粒剤に
おいて、単糖類および二糖類からなる群より選ばれる一
または二以上の糖を配合し、常法により粒剤にすること
により、この製剤を常用の高分子包材、例えばポリエチ
レン、ポリプロピレン、ポリエステル、塩化ビニル等で
包装して保存しても、粒剤中の塩酸ブロムヘキシンが高
分子包材へ吸着せず、粒剤中の塩酸ブロムヘキシン含量
を長期にわたって保持することを可能にするものである
[Means for Solving the Problems] The method of the present invention involves blending one or more sugars selected from the group consisting of monosaccharides and disaccharides in granules containing bromhexine hydrochloride, and granulating them by a conventional method. By making this into a granule, the bromhexine hydrochloride in the granules will not be adsorbed to the polymer packaging material even if this preparation is packaged and stored in commonly used polymer packaging materials such as polyethylene, polypropylene, polyester, vinyl chloride, etc. This makes it possible to maintain the bromhexine hydrochloride content in the granules for a long period of time.

以下、本発明を詳細に述べる。The present invention will be described in detail below.

本発明における粒剤は、第11改正日本薬局方に規定す
る顆粒剤および散剤を意味し、塩酸ブロムヘキシンを単
糖類および二糖類からなる群より選ばれる一または二以
上の糖とよく混合し、結合剤を用いて常法により製造す
る。
The granules used in the present invention refer to granules and powders defined in the 11th edition of the Japanese Pharmacopoeia, in which bromhexine hydrochloride is thoroughly mixed with one or more sugars selected from the group consisting of monosaccharides and disaccharides, and then combined. It is manufactured by a conventional method using an agent.

前記単糖類、二糖類として、マンニトール、ソルビトー
ル、ブドウ糖、乳糖、白糖等を用いる。
As the monosaccharides and disaccharides, mannitol, sorbitol, glucose, lactose, sucrose, etc. are used.

前記結合剤として、常用の結合剤、例えばヒドロキシプ
ロピルセルロース、ポリビニルピロリドン等を用いる。
As the binder, a commonly used binder such as hydroxypropylcellulose, polyvinylpyrrolidone, etc. is used.

この粒剤をポリエチレン、ポリプロピレン、ポリエステ
ル、塩化ビニル等の高分子包材(例えば積層アルミニウ
ム包材、容器等)で包装した場合は塩酸ブロムヘキシン
含量が経時的に低下することがない。
When this granule is packaged in a polymer packaging material such as polyethylene, polypropylene, polyester, or vinyl chloride (for example, a laminated aluminum packaging material, a container, etc.), the content of bromhexine hydrochloride does not decrease over time.

これに対し、デンプン、結晶セルロース[例えば商品名
アビセル、旭化成工業(株)製コ等を配合し、上記と同
様な製法で製造した粒剤は、同じ包材に包装した場合、
粒剤中の塩酸ブロムヘキシン含量が経時的に減少してし
まう。
On the other hand, when granules containing starch and crystalline cellulose (for example, Avicel (trade name), produced by Asahi Kasei Industries, Ltd.) and manufactured using the same manufacturing method as above, are packaged in the same packaging material,
The bromhexine hydrochloride content in the granules decreases over time.

[発明の効果コ 本発明の、単糖類および二糖類からなる群より選ばれる
一または二以上の糖を配合する方法により作られる塩酸
ブロムヘキシン含有粒剤は、ポリエチレン、ポリプロピ
レン、ポリエステル、塩化ビニル等の常用の高分子包材
で包装して保存しても、塩酸ブロムヘキシンがその高分
子包材に吸着することなく、粒剤中の塩酸ブロムヘキシ
ン含量を長期にわたって保持することができる。
[Effects of the Invention] The bromhexine hydrochloride-containing granules of the present invention, which are produced by the method of blending one or more sugars selected from the group consisting of monosaccharides and disaccharides, are made of polyethylene, polypropylene, polyester, vinyl chloride, etc. Even if the granules are packaged and stored using a commonly used polymer packaging material, the bromhexine hydrochloride content in the granules can be maintained for a long period of time without adsorption of bromhexine hydrochloride to the polymer packaging material.

[実施例コ 以下、本発明の実施例および試験例を示し、本発明をき
らに具体的に説明する。
[Example] Hereinafter, the present invention will be specifically explained by showing examples and test examples of the present invention.

(実施例1) 塩酸フロムヘキシン4g1マンニトール700gの混合
物を乳鉢に入れ、これにヒドロキシプロピルセルロース
14gをエタノール90gに溶解したものを結合剤とし
て加え、乳鉢中で練合した。練合後、12号のふるいを
通し、循環式乾燥器[DH−61、ヤマト科学(株)製
コにより60°Cで2時間乾燥した。
(Example 1) A mixture of 4 g of fromhexine hydrochloride and 700 g of mannitol was placed in a mortar, and a solution of 14 g of hydroxypropyl cellulose dissolved in 90 g of ethanol was added as a binder and kneaded in the mortar. After kneading, the mixture was passed through a No. 12 sieve and dried at 60°C for 2 hours in a circulating dryer [DH-61, manufactured by Yamato Scientific Co., Ltd.].

このうち、12号のふるいをとおり、14号のふるいに
残るものを選定し、顆粒剤680gを得た。
Of these, those that passed through a No. 12 sieve and remained on a No. 14 sieve were selected to obtain 680 g of granules.

これを製剤1とし、その720mgずつをポリエチレン
¥I!アルミニウム包材で分包、包装し、50°Cで4
週間保存したが、塩酸ブロムヘキシンの高分子包材への
吸着はほとんど起こらなかった。
This is Formulation 1, and each 720mg of polyethylene ¥I! Separate and wrap in aluminum packaging material and store at 50°C for 4 days.
Although it was stored for a week, there was almost no adsorption of bromhexine hydrochloride to the polymer packaging material.

(実施例2) マンニトール700gのかわりに乳@ 700gを使用
する他は、前記実施例1に準じて顆粒剤680gを得た
(Example 2) 680 g of granules were obtained in the same manner as in Example 1, except that 700 g of milk was used instead of 700 g of mannitol.

これを製剤2とし、その720mgずつを塩化ビニル積
層アルミニウム包材で分包、包装し、実施例1と同一条
件で保存したが、塩酸ブロムヘキシンの高分子包材への
吸着はほとんど起こらなかった。
This was designated as Formulation 2, and 720 mg of each was divided and packaged in vinyl chloride laminated aluminum packaging and stored under the same conditions as Example 1, but almost no adsorption of bromhexine hydrochloride to the polymer packaging material occurred.

(実施例3) 塩酸フロムヘキシン4g1マンニトール700乙の混合
物を乳鉢に入れ、これにヒドロキシプロピルセルロース
14gをエタノール90gに溶解したものを結合剤とし
て加え、乳鉢中で練合した。練合後、30号のふるいを
通し、循環式乾燥器[DN−61、ヤマト科学(株)製
コにより60°Cで2時間乾燥した。
(Example 3) A mixture of 4 g of fromhexine hydrochloride and 700 g of mannitol was placed in a mortar, and a solution of 14 g of hydroxypropyl cellulose dissolved in 90 g of ethanol was added as a binder and kneaded in the mortar. After kneading, the mixture was passed through a No. 30 sieve and dried at 60°C for 2 hours in a circulating dryer [DN-61, manufactured by Yamato Scientific Co., Ltd.].

これを30号のふるいにかけて通過したものを集め、散
剤700gを得た。
This was passed through a No. 30 sieve and the material that passed through was collected to obtain 700 g of powder.

これを製剤3とし、その720mgずつをポリエチレン
積欝アルミニウム包材で分包、包装し50°Cで4週間
保存したが、塩酸ブロムヘキシンの高分子包材への吸着
はほとんどなかった。
This was designated as Formulation 3, and 720 mg of each was divided and packaged in polyethylene bulk aluminum packaging and stored at 50°C for 4 weeks, but there was almost no adsorption of bromhexine hydrochloride to the polymer packaging.

(試験例1〉 製剤1および製剤2をそれぞれ、内側にポリエチレンを
MMしたアルミニウム包材に包装して加温条件下(50
°C)で保存し、1週間後、2週間後、3週間後および
4週間後に於ける包材中の塩酸ブロムヘキシン含量を、
下記の条件により、高速液体クロマトグラフ法を用いて
定量した。包材中の塩酸ブロムヘキシンについては、包
材をクロロホルム中で50℃、30分間還流した抽出液
について定量した。
(Test Example 1) Formulation 1 and Formulation 2 were each packaged in an aluminum packaging material with polyethylene MM inside and heated under heating conditions (50
°C), and the bromhexine hydrochloride content in the packaging material after 1 week, 2 weeks, 3 weeks, and 4 weeks,
It was quantified using high performance liquid chromatography under the following conditions. Bromhexine hydrochloride in the packaging material was quantified using an extract obtained by refluxing the packaging material in chloroform at 50°C for 30 minutes.

なお、マンニトールあるいは乳糖のかわりにそれぞれバ
レイショデンブンまたはアビセルを配合して実施例1に
準じて顆粒剤を製造し、これらをそれぞれ対照剤1、対
照剤2とし、製剤1および製剤2と同様にして定量した
In addition, granules were prepared according to Example 1 by blending potato starch or Avicel instead of mannitol or lactose, respectively, and these were used as Control Agent 1 and Control Agent 2, respectively, and were prepared in the same manner as Formulation 1 and Formulation 2. It was quantified.

定量条件 1)ポンプ ; HITACHI 655A−12[(
株)日立製作新製コ 2〉検出器 ; HITAC)II 655A[(株)
日立製作新製] 3)操作条件; 検出器  :紫外吸光光度計 測定波長 : 210nm 検出器感度: 0.04AUFS カラム  :内径4 mm 、長’;a 150mmの
ステンレス管に、充填剤としてオクタデシルシリル化し
た5μmのシリカゲルを充填する。
Quantitative conditions 1) Pump; HITACHI 655A-12 [(
Hitachi Seisakusho Co., Ltd. New Ko2〉Detector; HITAC) II 655A
Newly manufactured by Hitachi] 3) Operating conditions; Detector: Ultraviolet absorption photometer Measurement wavelength: 210 nm Detector sensitivity: 0.04 AUFS Column: Internal diameter 4 mm, length: a 150 mm stainless steel tube, octadecyl silylation as a packing material Fill with 5 μm silica gel.

カラム温度:50°C付近の一定温度 移動相  ニアセトニトリルと、ラウリル硫酸ナトリウ
ムの1/15Mリン酸二水素カリウム溶液の混液(混合
比520:480)流量   :毎分的1mlの一定流
量 4)注入量 ;塩酸ブロムヘキシン濃度20q/mQ程
度のものを10μ注入 (試験例2) 顆粒剤を包装する高分子包材に、ポリエチレン積層アル
ミニウム包材のかわりに塩化ビニル積層アルミニウム包
材を使用して、製剤1と対照剤1について前記試験例1
と同様にして定量試験を行なった。
Column temperature: Constant temperature mobile phase around 50°C Mixture of niacetonitrile and 1/15M potassium dihydrogen phosphate solution of sodium lauryl sulfate (mixing ratio 520:480) Flow rate: Constant flow rate of 1 ml per minute 4) Injection Amount: Inject 10 μ of bromhexine hydrochloride with a concentration of approximately 20 q/mQ (Test Example 2) A vinyl chloride laminated aluminum packaging material was used instead of a polyethylene laminated aluminum packaging material for the polymer packaging material used to package the granules. 1 and Comparative Agent 1 The above Test Example 1
A quantitative test was conducted in the same manner as above.

(試験例3) 顆粒剤を包装する高分子包材に、ポリエチレン積層アル
ミニウム包材のかわりにポリプロピレン類の気密容器を
使用して、製剤1と゛対照剤1について前記試験例1と
同様にして定量試験を行なった。
(Test Example 3) Preparation 1 and Control Agent 1 were quantitatively determined in the same manner as in Test Example 1, using a polypropylene airtight container instead of polyethylene laminated aluminum packaging as the polymer packaging material for the granules. I conducted a test.

(試験例4) 製剤1および製剤2のかわりに製剤3を用いる他は前記
試験例1と同様にして定量試験を行なった。
(Test Example 4) A quantitative test was conducted in the same manner as in Test Example 1 except that Formulation 3 was used instead of Formulation 1 and Formulation 2.

なお、マンニトールのかわりにバレイショデンブンを配
合して実施例3に準じて散剤を製造し、これを対照剤3
とし、製剤3と同様にして定量した。
In addition, a powder was prepared according to Example 3 by blending potato starch instead of mannitol, and this was mixed with Control Agent 3.
and quantified in the same manner as Formulation 3.

以上の試験例1〜3の結果を、製剤の製造直後に於ける
塩酸ブロムヘキシン含量に基づいて百分率で表示し、第
1表にまとめた。
The results of Test Examples 1 to 3 above are expressed in percentages based on the bromhexine hydrochloride content immediately after preparation of the preparations, and are summarized in Table 1.

Claims (1)

【特許請求の範囲】[Claims] (1)塩酸ブロムヘキシンを含有する粒剤において、単
糖類および二糖類からなる群より選ばれる一または二以
上の糖を配合することにより、高分子包材を用いて前記
粒剤を分包、保存する間に塩酸ブロムヘキシンが前記高
分子包材に吸着することを防止する方法。
(1) In the granules containing bromhexine hydrochloride, by blending one or more sugars selected from the group consisting of monosaccharides and disaccharides, the granules are packaged and stored using a polymer packaging material. A method for preventing bromhexine hydrochloride from being adsorbed to the polymer packaging material during the process.
JP61187395A 1986-08-09 1986-08-09 Bromhexine hydrochloride anti-adsorption formulation Expired - Lifetime JPH0739341B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61187395A JPH0739341B2 (en) 1986-08-09 1986-08-09 Bromhexine hydrochloride anti-adsorption formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61187395A JPH0739341B2 (en) 1986-08-09 1986-08-09 Bromhexine hydrochloride anti-adsorption formulation

Publications (2)

Publication Number Publication Date
JPS6344521A true JPS6344521A (en) 1988-02-25
JPH0739341B2 JPH0739341B2 (en) 1995-05-01

Family

ID=16205277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61187395A Expired - Lifetime JPH0739341B2 (en) 1986-08-09 1986-08-09 Bromhexine hydrochloride anti-adsorption formulation

Country Status (1)

Country Link
JP (1) JPH0739341B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552730A (en) * 1993-07-05 1996-09-03 Nec Corporation Mos differential voltage-to-current converter circuit with improved linearity
JP2007119453A (en) * 2005-09-29 2007-05-17 Daiichi Sankyo Healthcare Co Ltd Method for preventing lowering of bromhexine hydrochloride content

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54163820A (en) * 1978-05-26 1979-12-26 Thomae Gmbh Dr K Hyperglycemic kidney inflammation treating agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54163820A (en) * 1978-05-26 1979-12-26 Thomae Gmbh Dr K Hyperglycemic kidney inflammation treating agent

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552730A (en) * 1993-07-05 1996-09-03 Nec Corporation Mos differential voltage-to-current converter circuit with improved linearity
US5552729A (en) * 1993-07-05 1996-09-03 Nec Corporation MOS differential voltage-to-current converter circuit with improved linearity
US5598117A (en) * 1993-07-05 1997-01-28 Nec Corporation MOS differential voltage-to-current converter circuit with improved linearity
JP2007119453A (en) * 2005-09-29 2007-05-17 Daiichi Sankyo Healthcare Co Ltd Method for preventing lowering of bromhexine hydrochloride content

Also Published As

Publication number Publication date
JPH0739341B2 (en) 1995-05-01

Similar Documents

Publication Publication Date Title
US5387420A (en) Morphine-containing efferverscent composition
CN101606913B (en) Cefixime dispersing tablet and preparation methods thereof
CN110251477B (en) Mecobalamin tablet and preparation method thereof
CN102525963B (en) Netilmicin sulfate lyophiled powder injection and preparation method thereof
CN105434377A (en) Meisuoshuli tablet and preparation method thereof
SU1009467A1 (en) Agent for dissoluting urine concretions
JPS6344521A (en) Method for preventing adsorption of bromhexine hydrochloride
CN110507618A (en) A kind of Acetylcysteine granules agent and preparation method thereof
US3326760A (en) Choline salicylate polygalacturonate therapy
CA1334933C (en) Pharmaceutical composition and process for its preparation
CN113456605B (en) Sofos Wei Yuda Latavir double-layer tablet and preparation method thereof
CN108295035A (en) Procaterol Hydrochloride piece and preparation method thereof
JP2564822B2 (en) Bromhexine hydrochloride solid preparation
EP2915526A1 (en) Pharmaceutical compositions comprising anagrelide
CN85101689A (en) Nifedipine preparation and preparation method thereof
JP2986256B2 (en) Granules for hemodialysis
CN112587484A (en) Oseltamivir phosphate dry syrup and preparation method thereof
CN102058602B (en) Stable oral solid preparation containing losartan potassium and hydrochlorothiazide
CN113116827A (en) Oseltamivir phosphate granules and preparation method thereof
CN101138552A (en) Preparation method of almecillin V potassium granular formulation
US3681495A (en) Freeze dried echothiophate iodide compositions
JP2751933B2 (en) Preparation for hemodialysis and method for producing the same
CN113304118A (en) Ca-AKG effervescent tablet and preparation method thereof
CN112843001B (en) Amlodipine preparation and preparation method thereof
JPS62138432A (en) Stable tablet containing anti-inflammatory steroid

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term